Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
Ramalingam, S.S, Mazières, J, Planchard, D, Stinchcombe, T.E, Dy, G.K, Antonia, S.J, Horn, L, Lena, H, Minenza, E, Mennecier, B, Otterson, G.A, Campos, L.T, Gandara, D.R, Levy, B.P, Nair, S.G, Zalcman, G, Wolf, J, Baudelet, C, Lestini, B.J, Rizvi, N.A
Published in International journal of radiation oncology, biology, physics (01.12.2014)
Published in International journal of radiation oncology, biology, physics (01.12.2014)
Get full text
Journal Article
Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC)
Zalcman, G., Rizvi, N.A., Lena, H., Wolf, J., Mazieres, J., Antonia, S.J., Minenza, E., Planchard, D., Lestini, B.J., Ramalingam, S.S.
Published in Annals of oncology (01.04.2015)
Published in Annals of oncology (01.04.2015)
Get full text
Journal Article
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer
Ramalingam, S.S., Mazières, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G.A., Campos, L.T., Gandara, D.R., Levy, B.P., Nair, S.G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B.J., Rizvi, N.A.
Published in International journal of radiation oncology, biology, physics (01.12.2014)
Published in International journal of radiation oncology, biology, physics (01.12.2014)
Get full text
Journal Article